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Abstract
Background: Proteomic technologies applied for profiling human biofluids and blood cells are considered to
reveal new biomarkers of exposure or provide insights into novel mechanisms of adaptation.
Methods: Both a non-targeted (classical 2D-electrophoresis combined with mass spectrometry) as well as a
targeted proteomic approach (multiplex immunoassay) were applied to investigate how fasting for 36 h, as
compared to 12 h, affects the proteome of platelets, peripheral blood mononuclear cells (PBMC), plasma, urine and
saliva collected from ten healthy volunteers.
Results: Between-subject variability was highest in the plasma proteome and lowest in the PBMC proteome.
Random Forests analysis performed on the entire dataset revealed that changes in the level of the RhoGDI2
protein in PBMC and plasma ApoA4 levels were the two most obvious biomarkers of an extended fasting. Random
Forests (RF) analysis of the multiplex immunoassay data revealed leptin and MMP-3 as biomarkers for extended
fasting. However, high between-subject variability may have masked the extended fasting effects in the proteome
of the biofluids and blood cells.
Conclusions: Identification of significantly changed proteins in biofluids and blood cells using a non-targeted
approach, together with the outcome of targeted analysis revealed both known and novel markers for a 36 h
fasting period, including the cellular proteins RhoGDI2 and CLIC1, and plasma proteins ApoA4, leptin and MMP-3.
The PBMC proteome exhibited the lowest between-subject variability and therefore these cells appear to represent
the best biosamples for biomarker discovery in human nutrigenomics.
Background
There is an emerging demand on biomarker discovery
especially in the field of nutrition with respect to weight
regulation and obesity [1]. Proteomic technologies are
increasingly being applied in nutrition research to reveal
biomarkers that can help to demonstrate effectiveness of
certain diets. Furthermore, these technologies also aid
the discovery of mechanisms whereby dietary regimens
influence health [2,3]. Caloric restriction or fasting is a
popular and efficient way to reduce weight [4,5]. In this
study we investigated how an extended fasting period
from 12 h to 36 h is reflected in the proteome of several
body fluids and some of their cellular components. After
36 h fasting all glycogen resources are used [6]. The
proteomic applications used were classical 2D-electro-
phoresis combined with mass spectrometry for protein
identification, as a non-targeted approach, and a multi-
plex-based immunoassay, as a targeted approach. Our
aim was to see which type of application best detected
responses to a fasting period of 36 h and which body
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fluid or blood cells would be most appropriate to reflect
such responses.
This human trial was part of the European Nutrige-
nomics Organization (NuGO) Proof of Principal Study
(PPS) in which various omic techniques were applied
[7], including transcriptomics, proteomics and metabo-
lomics [8]. This component of the PPS was designed to
evaluate experimental and biological variation on the
individual level in nutrigenomic experiments as a basis
for future personalized nutrition concepts [9].
Methods
Study design and sample preparation
The goals and design of the human PPS have been
described recently [7]. Ethical permission for the study
was obtained from the North of Scotland Research
Ethics Services prior to the start of the study, and all
volunteers gave informed consent. Ten healthy volun-
teers (3 males and 7 females) were enrolled at the
Rowett Institute of Nutrition and Health, University of
Aberdeen. The BMI of volunteers ranged from 18.5 to
39.7 kg/m2 and the age of the volunteers ranged from
25 to 56 years. The volunteers were asked to come to
the Human Nutrition Unit once a week on different
days each week during a four week period after an over-
night fast to provide a blood sample (for the isolation of
plasma, PBMC and platelets) and a saliva and 24 h
urine sample. After the fourth sampling day, volunteers
were fasted for an additional 24 h (total of 36 h) fol-
lowed by sample collection (Figure 1). Blood samples
were collected into vacutainers containing potassium
EDTA anticoagulant. The isolation of platelets, PBMC,
plasma, saliva and urine were performed as described by
Crosley et al. [10]. Protein concentrations of platelets,
PBMC, saliva and urine were assessed by the RC/DC
assay (BioRad) according to the manufacturer’s instruc-
tions. The protein contents of plasma samples were
determined using 2-D Quant kits (GE Healthcare)
according to the manufacturer’s instructions. The sam-
ples were immediately aliquoted, snap frozen in liquid
nitrogen, stored at -80°C and shipped to the different
laboratories for analysis.
Analysis of plasma proteins by multiplex immunoassay
The concentrations of 89 proteins were measured by
Rules-Based Medicine (RBM) in all plasma samples by a
multiplex immunoassay (HumanMAP Version 1.6,
Rules-Based Medicine, Inc., Austin TX, USA).
2D-electrophoresis
The platelets and saliva were analyzed in laboratory 1,
PBMC and urine in laboratory 2 and depleted plasma in
laboratory 3. Each of the three laboratories ran one gel
per sampling time point, the 4 overnight fasting time
points were considered as replicates. 2D-electrophoresis
was performed as described previously [11]. Briefly, for
the blood related samples 200-250 μg protein was
loaded onto a 24 cm 4-7 linear IPG strip for separation
in the first dimension. Prior to IEF the plasma samples
were depleted of Albumin and IgG using the Albumin
and IgG Removal Kit (GE Healthcare) according to the
manufacturer’s instructions. The second dimension
separation was on a standard 12% SDS-PAGE for plate-
lets and PBMC, the second dimension of the depleted
plasma was separated on a 1 mm thick 10% Duracryl
gel [11]. For the saliva samples, 25 μg protein was
Figure 1 Schematic representation of the study design.
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loaded onto an 11 cm 4-7 linear IPG strip for separation
in the first dimension. The second dimension separation
was carried out on a 12% SDS-PAGE. For the urine
samples 300 μg protein was loaded onto an 18 cm pH
4-7 linear IPG strip. The gels with urine proteins were
stained with Coomassie. Gels with proteins obtained
from other biofluids and blood cells were stained with
Flamingo fluorescent stain (Biorad) according to the
manufacturer’s instructions. Spots were identified and
analyzed using the PDQuest v8.0 software (Biorad) for
the platelets and saliva; Delta2D v3.6 (Decodon) for the
PBMC and urine and Progenesis SameSpots v3.1 (Non-
linear Dynamics) for depleted plasma. Background sub-
traction and normalization were automatically carried
out by the software programs.
Protein identification
The selected protein spots were excised from the 2D
gels and processed for protein identification in the same
laboratory where the gels were run. Generation of tryp-
tic digest from the protein by in-gel digestion was per-
formed as described previously [11,12].
MALDI-TOF/TOF mass spectrometry
For MS/MS analysis of the spots from platelets and sal-
iva (laboratory 1), 1.0 μl of the peptide mixture and
1.0 μl matrix solution (2.5 mg/ml CHCA in 50% aceto-
nitrile/0.1% trifluoroacetic acid; TFA) were spotted on a
384-well MALDI target plate. Data were collected with
a MALDI-TOF/TOF mass spectrometer (4800 MALDI-
TOF/TOF Proteomics Analyzer, Applied Biosystems).
A default calibration was applied using a six-component
peptide standard spotted onto 13 different positions of
the MALDI target plate for MS, and Glu-Fibrinopeptide
B (m/z 1570,68) fragmentation for MS/MS. Typically,
1000 shots were combined for obtaining MS spectra and
for MS/MS spectra 2000 shots were combined. The GPS
Explorer v3.6 software (Applied Biosystems) was
employed to generate peak lists and automated MAS-
COT searches against the Swiss-Prot protein database
(Swiss-Prot release 56.5; 402 482 sequences) for protein
identification. One miss-cleavage was tolerated; carbami-
domethylation was set as a fixed modification and oxi-
dation of methionine as an optional modification. The
protein charge was set at 1+. The precursor tolerance
was set to 100 ppm and the MS/MS tolerance was set
at 0.2 Da. No restrictions were made on the protein
mass. Protein hits with a MASCOT protein score
greater than 56 (p < 0.05) and a GPS Explorer protein
score confidence index >95% were validated as con-
firmed identifications [13].
The identity of the plasma, PBMC and urine spots
(laboratory 2 and 3) was determined by peptide finger-
printing using an Ultraflex MALDI-TOF/TOF mass
spectrometer (Bruker Daltonics Ltd.). A 200 Hz nitrogen
laser was used to desorb/ionize the matrix/analyte mate-
rial, and ions were detected in positive ion reflectron
mode. All spectra were acquired automatically using the
Bruker fuzzy logic algorithm (FlexControl 3.0, Bruker)
and a Biotools 3.0 search routine. The resulting mass
data was interrogated using an offline version of the
MASCOT search engine (Matrix Science) using the
SPtrEMBL database with the following search criteria:
allowance of 0 or 1 missed cleavages; peptide mass tol-
erance of 50 ppm; trypsin as digestion enzyme; carbami-
domethyl modification of cysteine; methionine oxidation
as partial modification; and charged state as MH+ [14].
Statistical analysis
Exploratory analysis of the data indicated that a log-
transformation was advisable for most data sets. For rea-
sons of consistency all data sets were analyzed on a
log2-scale and back transformed to report fold changes.
For the extended fasting effect analysis, a linear model
including time point (5 levels) and subject (10 levels) as
factors was fitted to the 50 data points for each variable.
The extended fasting effect was then defined as a con-
trast that compared time point 5 (36 hours fasting) with
the average of the 4 baseline measurements (overnight
fasting). The 4 baseline time points were used to deter-
mine the between-subject effect, again using a linear
model with subject as the only factor. P-values were
adjusted for multiple testing within each data set by
using the Benjamini-Hochberg method.
Spots were selected for protein identification if their
adjusted p-value fell below 0.2 allowing a false discovery
rate (FDR) of 20%. Linear model analysis and P-value
adjustment were performed using the R package v2.10.1.
In order not to miss any interesting spots we also per-
formed additional analyses on the original scale and also
selected proteins with an adjusted P below 0.2 on this
scale. In this way we identified 10 proteins from the
2D-electrophoresis and 39 proteins for the multiplex
immunoassay which were significantly changed upon
the extended fasting. The data were imported into Gen-
eMaths v2.11 for discriminant principal component ana-
lysis and cluster analysis with Pearson correlation. We
used the R package v2.10.1 for random forests (RF) ana-
lysis, RF package 4.5-34 [15]. RF analysis was applied to
normalized data. The number of trees was set to 500
and the number of variables randomly sampled as can-
didates at each split was set to 9. Ten cycles were calcu-
lated and averaged. These average mean decreased Gini
results were plotted. The Gini importance indicates the
importance of the variable in the classification. Cytos-
cape v2.7 with the MiMI plug-in 3.0.1 was used to cre-
ate network associations. All proteomic data (2D and
RBM) where used for creating the network. The pro-
tein-protein interaction network was created using all
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available databases present in MiMI, among which are
IntAct, BIND and KEGG [16].
Results
In the proteome of most biofluids and blood cells an
effect of an extended fasting period from 12 h to 36 h
could be observed. However, the number of proteins
that changed as a result of the extended fasting was
relatively small compared to the large number of pro-
teins that differed significantly between subjects. Of the
2971 detected spots/proteins in all data sets, 153 spots/
proteins were changed due to extended fasting (5.1%),
whereas 914 mostly other spots/proteins exhibited sig-
nificant between-subject differences (30.8%). In plasma,
for example, extended fasting resulted in a significant
alteration of only 1.3% of the protein spots, whereas
69.1% of the spots differed significantly between
subjects, when using 2D-electrophoresis. Blood cells, on
the other hand, showed a remarkably lower number of
proteins that exhibited significant between-subject dif-
ferences (0.3% and 0.4% of the proteins in platelets and
PBMC, respectively). Moreover, PBMC showed the
highest number of proteins that changed significantly
when volunteers extended fasting from 12 h to 36 h
(9.1%). With the targeted approach using RBM, 39
plasma proteins (43.8%) changed significantly due to
extended fasting, and 78 proteins (87.6%) differed signif-
icantly between subjects (Table 1).
Using the 2D-electrophoresis approach we identified
proteins from spots with a relatively highly significant
adjusted p-value as a result of extended fasting: 5 spots
in plasma, 2 spots in PBMC, 1 spot in saliva and 2 spots
in urine (see Table 2 and Figure 2). Using the targeted
approach, we were able to identify 39 proteins that
changed significantly upon 36 h fasting compared to
overnight fasting (Table 3). The chloride intracellular
channel protein 1 (CLIC1) in PBMC exhibited a 5.3-fold
increase upon the fasting challenge. This was the most
pronounced change amongst all proteins (Table 2). C
reactive protein (CRP) was detected as increasing in
both the plasma 2D proteome and the RBM plasma
data set induced by extended fasting (Table 2 and 3).
Principal component analysis applied to the multiplex
immunoassay (RBM) data set revealed that each of the
subjects could be identified based on levels of 89 plasma
proteins (Figure 3). It appears that such data can be
used to provide a metabolic fingerprint of the individual
volunteers participating in this intervention study. How-
ever, this demonstrates that the between-subject effects
are larger than that of the fasting effect.
RF analysis applied to the full data set from non-tar-
geted and targeted proteomics applications, revealed
Table 1 Number of protein spots/proteins that change
during fasting challenge
Fasting
effect
Subject
effect
Total detected spots/
proteins
Non-targeted
approach
Plasma
proteomics
13 703 1018
PBMC proteomics 83 4 910
Platelet
proteomics
0 2 604
Saliva proteomics 1 69 208
Urine proteomics 3 58 142
Targeted
approach
Rules Based
Medicine
39 78 89
A fasting and a between-subject effect was observed.
Table 2 Protein identifications by MS/MS analysis of biofluid and blood cell proteins which were significantly
increased or decreased upon extended fasting (36 h), as compared with overnight fasting (12 h)
Sample
type
Spot Accession
#
Protein identification Fold-
change
p-value Adjusted
p-value
Mascot
score
Sequence
Coverage %
Matched
peptides
Plasma 1 P06727 Apolipoprotein A-IV (ApoA4) -1.80 <0.001 <0.001 426 69 34
2 P00738 Haptoglobin B chain -1.15 <0.001 0.009 87 32 8
3 P00738 Haptoglobin B chain fragment -1.14 <0.001 0.006 139 33 17
4 P36955 Pigment epithelium-derived
factor
-1.09 <0.001 0.061 113 35 16
5 P02741 C reactive protein (CRP) 1.42 <0.001 0.061 74 17 6
PBMC 6 P52566 Rho GDP-dissociation inhibitor 2
(RhoGDI2)
-2.78 <0.001 <0.001 63 23 4
7 O00299 Chloride intracellular channel
protein 1 (CLIC1)
5.30 <0.001 <0.001 73 23 4
Saliva 8 P01833 Polymeric-immunoglobulin
receptor (PIGR)
-3.16 <0.001 0.030 161 15 10
Urine 9 P02768 Serum albumin precursor 1.83 0.004 0.185 162 45 22
10 P02768 Serum albumin precursor 2.02 0.001 0.056 152 32 16
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that the Rho GDP-dissociation inhibitor 2 (RhoGDI2) in
PBMC and the plasma Apolipoprotein A-IV (ApoA4)
appeared the most significant biomarkers associated
with extended fasting (Figure 4a). RF analysis of the tar-
geted proteomics data set revealed leptin and matrix
metalloproteinase-3 (MMP-3) as biomarkers of extended
fasting (Figure 4b).
Cluster analysis with Pearson correlations between the
fold-change in RBM plasma proteins after extended fast-
ing versus overnight fasting is shown in Figure 5. Leptin
Figure 2 Identified proteins marked on 2D gels representing plasma (A), PBMC (B), saliva (C), urine (D) and platelets (E). The numbers
refer to those used in Table 2.
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and Insulin-like growth factor I (IGF-1) are correlated
and closely clustered to each other. Both proteins are
down-regulated after extended fasting (Table 3). CRP is
correlated to changes in alpha-2-macroglobulin, serum
amyloid P and adiponectin (Figure 5). The close associa-
tion between CRP, serum amyloid P and alpha-2-macro-
globulin is confirmed in the protein-protein interaction
network shown in Figure 6. In addition, leptin changes
appear directly linked to changes in CRP and alpha-2-
macroglobulin, whereas MMP-3 appears directly linked
to alterations in the tissue inhibitor of metalloprotei-
nase-1 (TIMP-1), monocyte chemotactic protein-1
(MCP-1) and plasminogen activator inhibitor-1 (PAI-1).
Discussion
This study, using both non-targeted as well as targeted
proteomic approaches applied to biofluids and blood
cells to elucidate changes in their proteomes induced by
Table 3 Plasma proteins of which absolute levels significantly changed due to extended fasting (36 h) compared with
overnight fasting (12 h), as assessed using the multiplex immunoassay (RBM)
Protein Accession # Fold-change p-value Adjusted p-value
IGF-1 P01343 -2.72 <0.001 <0.001
Leptin P41159 -2.59 <0.001 <0.001
Erythropoietin P01588 -1.56 0.080 0.187
IgE n.a. -1.54 0.002 0.013
IL-8 P10145 -1.51 <0.001 0.001
MMP-3 P08254 -1.48 <0.001 <0.001
Thyroid Stimulating Hormone P01222 -1.47 <0.001 <0.001
Insulin P01308 -1.29 <0.001 0.001
Carcinoembryonic Antigen P06731 -1.29 0.037 0.116
IL-1beta P01584 -1.19 <0.001 <0.001
PAI-1 P05121 -1.19 0.002 0.013
Apolipoprotein A-1 (ApoA1) P02647 -1.18 0.006 0.025
MCP-1 P13500 -1.17 <0.001 0.001
Eotaxin P51671 -1.16 0.001 0.005
VEGF P15692 -1.14 <0.001 <0.001
IL-16 Q14005 -1.13 <0.001 0.002
EGF P01133 -1.12 0.085 0.190
IL-18 Q14116 -1.12 0.013 0.048
Alpha-Fetoprotein P02771 -1.12 <0.001 <0.001
Fatty Acid Binding Protein P05413 -1.07 0.006 0.025
IgA n.a. -1.07 0.043 0.116
Factor VII (F7) P08709 -1.06 0.061 0.157
Creatine Kinase-MB P06732 -1.04 0.075 0.181
IL-10 P22301 -1.04 0.041 0.116
Glutathione S-Transferase P09211 -1.04 0.010 0.041
Tissue Factor (TF) P13726 -1.03 0.004 0.019
Prostatic Acid Phosphatase P15309 -1.03 0.018 0.067
Alpha-2 Macroglobulin (A2M) P01023 1.02 0.021 0.072
Complement 3 P01024 1.02 0.028 0.092
TIMP-1 P01033 1.02 0.005 0.025
IL-12p70 P29459 1.03 0.038 0.116
VCAM-1 P19320 1.05 0.011 0.044
Serum Amyloid P (SAP) P02743 1.07 0.072 0.179
Lipoprotein (a) P08519 1.09 0.041 0.116
MIP-1beta P13236 1.09 0.048 0.127
TNF-alpha P01375 1.10 0.042 0.116
EN-RAGE P80511 1.17 0.085 0.190
Ferritin P02794 1.27 <0.001 0.001
C Reactive Protein (CRP) P02741 1.55 <0.001 0.002
n.a. = no accession #.
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extended fasting, revealed substantial between-subject
variability which may mask the true biological effect of
fasting on the proteome. This suggests that any nutrige-
nomic experiment require a sufficient number of repli-
cates and matched samples to identify the usually rather
subtle changes that dietary maneuvers may impose.
Levels of between-subject variability were higher in all
biofluids samples as compared to the cellular proteomes.
In this study, PBMC exhibited the largest number of sig-
nificant changes in protein levels following the extended
fast. RF analysis on the entire data set revealed that in
PBMC the RhoGDI2 and plasma ApoA4 proteins were
the most significant biomarkers for extended fasting. RF
analysis of the multiplex immunoassay data set revealed
leptin and MMP-3 as potential biomarkers for extended
fasting.
It should be noted that the between-subject variation
may in part be due to the heterogeneous composition of
our study cohort with regard to various parameters,
including gender and BMI. Consequently, this type of
variability can be reduced by selecting a more homoge-
neous study population. We observed markedly less
inter-individual difference in the PBMC proteome than
we observed previously in the PBMC transcriptome of
PBMC from human volunteers who were participating
in a study with a similar baseline design [17]. In our
study 0.4% of the PBMC proteins detected differed sig-
nificantly between individuals compared with 39% of
PBMC transcripts [17].
Most interesting biomarkers that are involved in meta-
bolic pathways, as well as those related to inflammation
and oxidative stress, are present only in very low con-
centrations in biosamples. In these cases, their low
abundance prevents detection by classical proteomic
techniques such as 2D-electrophoresis [18]. Multiplex
immunoassays are therefore an interesting alternative
because they are more sensitive compared to 2D-elec-
trophoresis [19]. Indeed, a wide range of plasma protein
changes caused by extended fasting were detected using
the targeted multiplex immunoassay method. However,
a big advantage of 2D-electrophoresis is that it can
visualize isoforms and possible protein modifications,
whereas with an antibody-based approach this depends
on the availability of isoform-specific antibodies.
CLIC1 in PBMC was the protein that exhibited the
largest fold-change as a result of the extended fasting.
In general, chloride channels play important roles in the
regulation of cellular excitability, transepithelial trans-
port, cell volume regulation, and acidification of intra-
cellular organelles [20]. CLIC1 is responsible for
stabilization of the membrane potential, which could be
influenced by the nutrient status in PBMC. Moreover
CLIC1 seems to be associated with cellular stress
response mechanisms and starvation may be interpreted
as a metabolic stress condition [21].
Besides CLIC1, levels of RhoGDI2 and ApoA4 were
the best indicators of the extended fasting state based
on analysis of all the proteomic data. Insulin has the
ability to relocate RhoGDI2 to the membrane [22].
Since plasma glucose and insulin levels are low during
fasting, the relative amount of RhoGDI2 in the cytosol
of PBMC might be predicted to increase during
extended fasting. Since by 2D preferentially cytosolic
proteins are detected, RhoGDI2 is expected to rise in
spot intensity. However, a decrease was noticed in our
experiment indicating that cytosolic RhoGDI2 concen-
tration is influenced by other factors like posttransla-
tional modification or turn-over rate.
ApoA4 is a major component of chylomicrons and is
synthesized by the small intestine. It is proposed to
represent a circulating satiety signal [23] and after fast-
ing, therefore, may decrease its levels [24].
IGF-1, leptin and CRP were the proteins with the big-
gest negative and positive fold change upon the fasting
challenge in the RBM data. Circulating IGF-1 levels are
associated with dietary protein intake [25,26]. This
could explain why after an extended fast without protein
intake, IGF-1 is decreased [27]. The decrease of leptin is
as expected because it is known to be a positive marker
for fasting or weight loss [28-30]. Chan et al. [31] have
shown that leptin and IGF-1 levels decrease after a 72 h
fasting. Our correlation analysis clustered IGF-1 and
leptin suggesting that adipose tissue, as the main source
of leptin, and liver, as the origin of circulating IGF-1,
undergo metabolic adaptation via a closely linked
mechanism. CRP is an acute phase protein and its eleva-
tion after this short term fasting might therefore be
Figure 3 PCA analysis of data obtained from the multiplex
immunoassay (RBM). Each color represents a different subject.
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Figure 4 Biomarkers of extended fasting effect calculated by Random Forrest analysis. Panel A: results obtained from analysis of all
proteomic data (2D and RBM). Panel B: results obtained from targeted proteomic analysis using multiplex immunoassay (RBM). The spot
numbers between brackets refer to those used in Table 2. Proteins without numbers between brackets refer to those used in Table 3.
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expected, although after long term fasting or caloric
restriction CRP is usually down-regulated [32]. RF
analysis applied to the RBM data revealed leptin and
MMP-3 as the most obvious biomarkers for a fasting
challenge. No direct interaction between leptin and
MMP-3 has been reported so far. A possible mechanism
could be the inverse correlation between leptin and
adiponectin levels [19,33] since the leptin/adiponectin
ration changes during extended fasting. Adiponectin by
itself has the ability to increase TIMP1, which is able to
inhibit the activity of MMPs [34,35]. However, adipo-
nectin plasma levels did not change significantly (p =
0.45) upon the extended fasting.
Most interestingly, the correlation analysis clustered
CRP closely together with adiponectin, serum amyloid P
and alpha-2-macroglobulin. Except for adiponectin, a
networking interaction analysis using MiMI, places
those proteins together with leptin and RhoGDI2. An
interaction between leptin and CRP, which are positively
correlated in normal weight, overweight and obese
subjects [36], was described by Chen et al [37]. Alpha-2-
microglobulin is described as a leptin binding protein
[38]. This interaction may be involved in the clearance
of leptin by the alpha-2-microglobulin receptor.
Another observation from the networking analysis was
an interaction between PAI-1, MMP-3, MCP1 and
TIMP1. As mentioned above, TIMP1 inhibits the activ-
ity of MMPs [34,35], whereas both PAI-1 and MCP1 are
inactivated through proteolysis mediated by MMP-3
[39,40]. This interaction between MMP-3 and MCP-1
may be the reason that MMP-3 is ranked relatively high
by the RF analysis. An inhibition or decrease of PAI-1
leads to a reduction of fat depots and adipocyte volume
[41]. Several studies have shown that PAI-1 is increased
in adipose tissue and plasma in obese humans and that
plasma PAI-1 concentrations decrease after weight loss
or fasting [42,43], which suggests a role for this protei-
nase inhibitor in the development and maintenance of
obesity. Jensen et al. [44] reported that a low glycemic
index diet in overweight adults could be beneficial in
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regulating fasting concentrations of the cardiovascular
disease risk factor PAI-1 showing that PAI-1 concentra-
tions are sensitive to the nutritional status. PAI-1,
TIMPs and MMPs play a role in extracellular matrix
remodeling [41,45,46]. Interestingly, a correlation has
been described between CRP and PAI-1 [47,48], linking
both interaction networks.
Conclusions
Both non-targeted and targeted proteomic analysis on a
range of human body fluid samples and selected blood
cells examining the effect of an extended fasting revealed
that there is a considerable between-subject effect with
the lowest variability in the PBMC proteome. These cells
may therefore be considered as a prime sample source in
further nutrigenomic studies when proteomic technolo-
gies are applied for biomarker discovery. The antibody
based analysis is superior when plasma proteins are ana-
lyzed and reveals a distinct metabolic fingerprint that
identifies the individuals. The protein panel that charac-
terizes extended fasting by the most significant changes
comprises known entities such as leptin, ApoA4 and
IGF-1, but also a variety of novel markers including
RhoGDI2, CLIC1 and MMP-3. These candidate biomar-
kers could be of interest in future nutrition studies.
Acknowledgements
This research was supported by NuGO (The European Nutrigenomics
Organization: linking genomics, nutrition and health research; CT-2004-
505944). The Rowett Institute of Nutrition and Health is funded by the
Scottish Government Rural and Environment Research and Analysis
Directorate (RERAD). The Institute of Food Research is funded by the
Biotechnology and Biological Sciences Research Council (BBSRC). We also
thank Barbara Gelhaus for her excellent analysis of the PBMC and urine
samples. We thank Ping Wang for the help of the random forests analysis.
Author details
1Department of Human Biology, NUTRIM, Maastricht University, Maastricht,
the Netherlands. 2Rowett Institute of Nutrition and Health, University of
Aberdeen, Aberdeen, UK. 3Molecular Nutrition Unit, ZIEL - Research Center
for Nutrition and Food Sciences, Technische Universität München, Freising-
Weihenstephan, Germany. 4Biomathematics and Statistics Scotland,
Aberdeen, UK. 5Institute of Food Research, Norwich Research Park, Norwich,
UK. 6Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University,
Maastricht, the Netherlands.
Authors’ contributions
FB designed and performed the experiments, analyzed the data and wrote
the manuscript. BR conceived, designed and coordinated the study,
analyzed the data. IRA designed the study, performed the experiments and
analyzed the data. KC designed the study and collected the samples. SD
designed and coordinated the study. CM collected the raw data and
performed the statistic analysis. GH performed the statistic analysis. AP
designed and performed the experiments. CH designed and performed the
experiments. SC participated in the data analysis. CE participated in the data
analysis. FM designed the study and performed the experiments. IJ designed
the study and performed the experiments. RE designed and coordinated the
study, performed the experiments and analyzed the data. HD designed and
coordinated the study. EM designed and coordinated the study and
participated in manuscript writing. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 October 2010 Accepted: 25 March 2011
Published: 25 March 2011
References
1. Kussmann M, Raymond F, Affolter M: OMICS-driven biomarker discovery
in nutrition and health. Journal of biotechnology 2006, 124(4):758-787.
2. de Roos B: Nutrition proteomics and biomarker discovery. Expert review of
proteomics 2009, 6(4):349-351.
3. de Roos B, McArdle HJ: Proteomics as a tool for the modelling of
biological processes and biomarker development in nutrition research.
The British journal of nutrition 2008, 99(Suppl 3):S66-71.
4. Johnstone AM: Fasting - the ultimate diet? Obes Rev 2007,
8(3):211-222.
5. Bahadori B, McCarty MF, Barroso-Aranda J, Gustin JC, Contreras F: A “mini-
fast with exercise” protocol for fat loss. Medical hypotheses 2009,
73(4):619-622.
6. Cahill GF Jr: Fuel metabolism in starvation. Annual review of nutrition 2006,
26:1-22.
7. Baccini M, Bachmaier EM, Biggeri A, Boekschoten MV, Bouwman FG,
Brennan L, Caesar R, Cinti S, Coort SL, Crosley K, et al: The NuGO proof of
principle study package: a collaborative research effort of the European
Nutrigenomics Organisation. Genes & nutrition 2008, 3(3-4):147-151.
8. Rubio-Aliaga I, de Roos B, Duthie SJ, Crosley LK, Mayer C, Horgan G,
Colquhoun IJ, Le Gall G, Huber F, Kremer W, et al: Metabolomics of
prolonged fasting in humans: from physiology to individual
metabotypes. Metabolomics .
9. Kussmann M, Rezzi S, Daniel H: Profiling techniques in nutrition and
health research. Current opinion in biotechnology 2008, 19(2):83-99.
10. Crosley LK, Duthie SJ, Polley AC, Bouwman FG, Heim C, Mulholland F,
Horgan G, Johnson IT, Mariman EC, Elliott RM, et al: Variation in protein
levels obtained from human blood cells and biofluids for platelet,
peripheral blood mononuclear cell, plasma, urine and saliva proteomics.
Genes & nutrition 2009, 4(2):95-102.
11. de Roos B, Duthie SJ, Polley AC, Mulholland F, Bouwman FG, Heim C,
Rucklidge GJ, Johnson IT, Mariman EC, Daniel H, et al: Proteomic
methodological recommendations for studies involving human plasma,
Figure 6 Protein-protein interaction networking based on the
outcome of the total dataset. Red represents a decrease and green
an increase in protein levels. The size of the circle represents the fold
change levels. The short protein names shown in the network refer to
Table 2 and 3. Alpha-1-microglobulin (AMBP) was down-regulated and
ApoA1 was up-regulated in urine, but not significantly (data not shown).
Bouwman et al. BMC Medical Genomics 2011, 4:24
http://www.biomedcentral.com/1755-8794/4/24
Page 10 of 12
platelets, and peripheral blood mononuclear cells. Journal of proteome
research 2008, 7(6):2280-2290.
12. Bouwman F, Suylen D, Renes J, Mariman E: Evaluation and improving
the success rate of protein identification by peptide mass
fingerprinting using matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry. Rapid Commun Mass Spectrom 2005,
19(17):2465-2468.
13. Cranenburg EC, Vermeer C, Koos R, Boumans ML, Hackeng TM,
Bouwman FG, Kwaijtaal M, Brandenburg VM, Ketteler M, Schurgers LJ: The
circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker
for cardiovascular calcification. Journal of vascular research 2008,
45(5):427-436.
14. Fuchs D, Dirscherl B, Schroot JH, Daniel H, Wenzel U: Proteome analysis
suggests that mitochondrial dysfunction in stressed endothelial cells is
reversed by a soy extract and isolated isoflavones. Journal of proteome
research 2007, 6(6):2132-2142.
15. Breiman L: Random forests. Machine Learning 2001, 45(1):5-32.
16. Gao J, Ade AS, Tarcea VG, Weymouth TE, Mirel BR, Jagadish HV, States DJ:
Integrating and annotating the interactome using the MiMI plugin for
cytoscape. Bioinformatics (Oxford, England) 2009, 25(1):137-138.
17. Eady JJ, Wortley GM, Wormstone YM, Hughes JC, Astley SB, Foxall RJ,
Doleman JF, Elliott RM: Variation in gene expression profiles of peripheral
blood mononuclear cells from healthy volunteers. Physiol Genomics 2005,
22(3):402-411.
18. Kenyon GL, DeMarini DM, Fuchs E, Galas DJ, Kirsch JF, Leyh TS, Moos WH,
Petsko GA, Ringe D, Rubin GM, et al: Defining the mandate of proteomics
in the post-genomics era: workshop report. Mol Cell Proteomics 2002,
1(10):763-780.
19. Schipper HS, de Jager W, van Dijk ME, Meerding J, Zelissen PM, Adan RA,
Prakken BJ, Kalkhoven E: A Multiplex Immunoassay for Human Adipokine
Profiling. Clinical chemistry 2010, 56(8):1320-1328.
20. Nilius B, Droogmans G: Amazing chloride channels: an overview. Acta
physiologica Scandinavica 2003, 177(2):119-147.
21. Wang P, Bouwman FG, Mariman EC: Generally detected proteins in
comparative proteomics–a matter of cellular stress response? Proteomics
2009, 9(11):2955-2966.
22. Shisheva A, Buxton J, Czech MP: Differential intracellular localizations of
GDP dissociation inhibitor isoforms. Insulin-dependent redistribution of
GDP dissociation inhibitor-2 in 3T3-L1 adipocytes. The Journal of
biological chemistry 1994, 269(39):23865-23868.
23. Tso P, Chen Q, Fujimoto K, Fukagawa K, Sakata T: Apolipoprotein A-IV: a
circulating satiety signal produced by the small intestine. Obesity research
1995, 3(Suppl 5):689S-695S.
24. Bertile F, Schaeffer C, Le Maho Y, Raclot T, Van Dorsselaer A: A proteomic
approach to identify differentially expressed plasma proteins between
the fed and prolonged fasted states. Proteomics 2009, 9(1):148-158.
25. Hoppe C, Udam TR, Lauritzen L, Molgaard C, Juul A, Michaelsen KF: Animal
protein intake, serum insulin-like growth factor I, and growth in healthy
2.5-y-old Danish children. The American journal of clinical nutrition 2004,
80(2):447-452.
26. Hoppe C, Kristensen M, Boiesen M, Kudsk J, Fleischer Michaelsen K,
Molgaard C: Short-term effects of replacing milk with cola beverages on
insulin-like growth factor-I and insulin-glucose metabolism: a 10 d
interventional study in young men. The British journal of nutrition 2009,
102(7):1047-1051.
27. Longo VD, Fontana L: Calorie restriction and cancer prevention:
metabolic and molecular mechanisms. Trends in pharmacological sciences
2010, 31(2):89-98.
28. Stefan N, Fritsche A, Haring H, Stumvoll M: Acute stimulation of leptin
concentrations in humans during hyperglycemic hyperinsulinemia.
Influence of free fatty acids and fasting. Int J Obes Relat Metab Disord
2001, 25(1):138-142.
29. Chan JL, Mietus JE, Raciti PM, Goldberger AL, Mantzoros CS: Short-term
fasting-induced autonomic activation and changes in catecholamine
levels are not mediated by changes in leptin levels in healthy humans.
Clinical endocrinology 2007, 66(1):49-57.
30. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E,
Flier JS: Role of leptin in the neuroendocrine response to fasting. Nature
1996, 382(6588):250-252.
31. Chan JL, Williams CJ, Raciti P, Blakeman J, Kelesidis T, Kelesidis I,
Johnson ML, Thorner MO, Mantzoros CS: Leptin does not mediate short-
term fasting-induced changes in growth hormone pulsatility but
increases IGF-I in leptin deficiency states. The Journal of clinical
endocrinology and metabolism 2008, 93(7):2819-2827.
32. Fontana L, Meyer TE, Klein S, Holloszy JO: Long-term calorie restriction is
highly effective in reducing the risk for atherosclerosis in humans.
Proceedings of the National Academy of Sciences of the United States of
America 2004, 101(17):6659-6663.
33. Matsubara M, Maruoka S, Katayose S: Inverse relationship between plasma
adiponectin and leptin concentrations in normal-weight and obese
women. European journal of endocrinology/European Federation of Endocrine
Societies 2002, 147(2):173-180.
34. Chen TH, Chen L, Hsieh MS, Chang CP, Chou DT, Tsai SH: Evidence for a
protective role for adiponectin in osteoarthritis. Biochimica et biophysica
acta 2006, 1762(8):711-718.
35. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K,
Maeda K, Nagaretani H, Kishida K, Maeda N, et al: Adiponectin
specifically increased tissue inhibitor of metalloproteinase-1 through
interleukin-10 expression in human macrophages. Circulation 2004,
109(17):2046-2049.
36. Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE,
Berger PB, Somers VK: Independent association between plasma leptin
and C-reactive protein in healthy humans. Circulation 2004,
109(18):2181-2185.
37. Chen K, Li F, Li J, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M,
Skibinski GA, McCrory MA, et al: Induction of leptin resistance through
direct interaction of C-reactive protein with leptin. Nature medicine 2006,
12(4):425-432.
38. Birkenmeier G, Kampfer I, Kratzsch J, Schellenberger W: Human leptin
forms complexes with alpha 2-macroglobulin which are recognized by
the alpha 2-macroglobulin receptor/low density lipoprotein receptor-
related protein. European journal of endocrinology/European Federation of
Endocrine Societies 1998, 139(2):224-230.
39. Lijnen HR, Arza B, Van Hoef B, Collen D, Declerck PJ: Inactivation of
plasminogen activator inhibitor-1 by specific proteolysis with
stromelysin-1 (MMP-3). The Journal of biological chemistry 2000,
275(48):37645-37650.
40. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I,
Overall CM: Matrix metalloproteinase processing of monocyte
chemoattractant proteins generates CC chemokine receptor
antagonists with anti-inflammatory properties in vivo. Blood 2002,
100(4):1160-1167.
41. Mariman EC, Wang P: Adipocyte extracellular matrix composition,
dynamics and role in obesity. Cell Mol Life Sci 2010, 67(8):1277-1292.
42. Mavri A, Alessi MC, Bastelica D, Geel-Georgelin O, Fina F, Sentocnik JT,
Stegnar M, Juhan-Vague I: Subcutaneous abdominal, but not femoral fat
expression of plasminogen activator inhibitor-1 (PAI-1) is related to
plasma PAI-1 levels and insulin resistance and decreases after weight
loss. Diabetologia 2001, 44(11):2025-2031.
43. Murakami T, Horigome H, Tanaka K, Nakata Y, Ohkawara K, Katayama Y,
Matsui A: Impact of weight reduction on production of platelet-derived
microparticles and fibrinolytic parameters in obesity. Thrombosis research
2007, 119(1):45-53.
44. Jensen L, Sloth B, Krog-Mikkelsen I, Flint A, Raben A, Tholstrup T, Brunner N,
Astrup A: A low-glycemic-index diet reduces plasma plasminogen
activator inhibitor-1 activity, but not tissue inhibitor of proteinases-1 or
plasminogen activator inhibitor-1 protein, in overweight women. The
American journal of clinical nutrition 2008, 87(1):97-105.
45. Baker EA, Leaper DJ: The plasminogen activator and matrix
metalloproteinase systems in colorectal cancer: relationship to tumour
pathology. Eur J Cancer 2003, 39(7):981-988.
46. Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van
Obberghen E, Tartare-Deckert S: Matrix metalloproteinases are
differentially expressed in adipose tissue during obesity and modulate
adipocyte differentiation. The Journal of biological chemistry 2003,
278(14):11888-11896.
47. Kraja AT, Province MA, Arnett D, Wagenknecht L, Tang W, Hopkins PN,
Djousse L, Borecki IB: Do inflammation and procoagulation biomarkers
Bouwman et al. BMC Medical Genomics 2011, 4:24
http://www.biomedcentral.com/1755-8794/4/24
Page 11 of 12
contribute to the metabolic syndrome cluster? Nutrition & metabolism
2007, 4:28.
48. Gnacinska M, Malgorzewicz S, Guzek M, Lysiak-Szydlowska W, Sworczak K:
Adipose tissue activity in relation to overweight or obesity.
Endokrynologia Polska 2010, 61(2):160-168.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1755-8794/4/24/prepub
doi:10.1186/1755-8794-4-24
Cite this article as: Bouwman et al.: 2D-electrophoresis and multiplex
immunoassay proteomic analysis of different body fluids and cellular
components reveal known and novel markers for extended fasting.
BMC Medical Genomics 2011 4:24.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bouwman et al. BMC Medical Genomics 2011, 4:24
http://www.biomedcentral.com/1755-8794/4/24
Page 12 of 12
